Total amount raised
$13.3 Millions
Latest funding date
01/01/2022
Location
Fauna Bio has successfully raised significant funding through various rounds, including a notable multi-year $494 million agreement with Eli Lilly for preclinical drug discovery in obesity. The company leverages its proprietary Convergence™ AI platform to harness the disease resistance mechanisms of diverse animal species, aiming to develop innovative healthcare solutions for humans.
With a total of 13 investors backing its mission, Fauna Bio continues to make strides in the biotechnology sector by exploring novel therapeutic targets. Keep reading to delve into the intricacies of Fauna Bio's fundraising journey and the investors supporting this groundbreaking platform.
What Is Fauna Bio?
Fauna Bio, founded in 2018, is a biotechnology company based in Berkeley, California. The company leverages the science of hibernation and other evolved disease resistance mechanisms in animals to improve human healthcare. With a team of 11-50 employees, Fauna Bio focuses on developing new therapeutic drugs using its proprietary Convergence™ AI platform.
The company was founded by Ashley Zehnder, Katie Grabek, and Linda Goodman. Fauna Bio collaborates with major pharmaceutical companies and engages in space-focused research programs, aiming to create innovative solutions for diseases such as heart disease and neurodegenerative disorders.
How Much Funding Has Fauna Bio Raised?
- Venture Round
- Amount Raised: Not publicly disclosed
- Date: January 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing research and development efforts.
- Seed Round
- Amount Raised: $9M
- Date: September 2021
- Lead Investors: LifeForce Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the Convergence™ AI platform and accelerate the discovery of new therapeutic targets.
- Seed Round
- Amount Raised: Not publicly disclosed
- Date: July 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop the company's drug discovery initiatives.
- Grant
- Amount Raised: Not publicly disclosed
- Date: March 2021
- Lead Investors: National Human Genome Research Institute
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support genomic research and development.
- Grant
- Amount Raised: $229K
- Date: October 2019
- Lead Investors: National Institutes of Health
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund research in heart disease and related disorders.
- Seed Round
- Amount Raised: $4.1M
- Date: April 2019
- Lead Investors: True Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To launch the Convergence™ AI platform and begin initial drug discovery efforts.
Total Amount Raised: $13.329M. Current Valuation: Not publicly disclosed.
Key Investors
- LifeForce Capital
- Details: LifeForce Capital is a venture capital firm investing in healthcare's most impactful software-driven companies. They focus on improving care delivery at scale and enabling more efficient therapeutic development through computational biology.
- Investment Focus Areas: Healthcare, software-driven companies, computational biology
- Notable Investments: Not publicly disclosed
- True Ventures
- Details: True Ventures is a venture capital firm that invests in early-stage technology startups. They have a strong track record of supporting innovative companies from their inception.
- Investment Focus Areas: Early-stage technology startups
- Notable Investments: Peloton, Ring, Blue Bottle Coffee
- National Human Genome Research Institute
- Details: The National Human Genome Research Institute is a part of the National Institutes of Health, focusing on advancing human health through genomic research. They support a wide range of research initiatives aimed at understanding the human genome.
- Investment Focus Areas: Genomic research, human health, scientific innovation
- Notable Investments: Not publicly disclosed
- National Institutes of Health
- Details: The National Institutes of Health is the primary agency of the United States government responsible for biomedical and public health research. They fund a vast array of research projects aimed at improving health and saving lives.
- Investment Focus Areas: Biomedical research, public health, medical innovation
- Notable Investments: Not publicly disclosed
- BioMed Ventures
- Details: BioMed Ventures is the investment arm of BioMed Realty, focusing on life sciences and healthcare investments. They support companies that are at the forefront of medical innovation.
- Investment Focus Areas: Life sciences, healthcare, medical devices
- Notable Investments: Not publicly disclosed
What's Next for Fauna Bio?
Fauna Bio stands at the cusp of significant opportunities, driven by its innovative Convergence™ AI platform. The company is poised to expand its drug discovery efforts, particularly in areas like neurologic, metabolic, fibrotic, and cardiovascular disorders. Collaborations with major pharmaceutical companies, such as Novo Nordisk, further amplify its potential to identify novel genetic targets and develop groundbreaking therapies.
As Fauna Bio advances its research, future fundraising opportunities are likely to emerge. The company may seek additional investment to support clinical trials and further development of its therapeutic pipeline. However, challenges such as regulatory hurdles and competition from other biotech firms could pose obstacles. Navigating these complexities will be crucial for Fauna Bio's continued success and growth in the biotechnology sector.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Fauna Bio and gather other critical business insights. Sign up for free and unlock the potential of data-driven decision-making today.
